CSF2 and melanoma: A randomized clinical study in 245 unresectable stage III-IV melanoma patients evaluated ipilimumab at 10 mg/kg intravenously on day 1 and GM-CSF at 250 μg subcutaneously on days 1–14 of each 21-day cycle [36].